You are here: Industry Insights > Market News

News List

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY PR Newswire
March 25, 2025
Henlius reported 2024 results with rising revenue and profit. It advanced in oncology, expanded globally, and made pipeline progress.
Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines PR Newswire
March 25, 2025
Glenmark partners with HFI and Malinao to launch a nutrition program in PH, targeting children & women, with 3 key interventions.
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14 PR Newswire
March 24, 2025
EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development.
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates PR Newswire
March 24, 2025
AIM Vaccine's mRNA shingles vaccine got FDA clinical trial approval. Its platform has advantages, AI empowers it, and the vaccine market has great potential.
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China PR Newswire
March 24, 2025
ArkBio completed AK0901's Phase III study for ADHD. It's a novel drug with good results, set to offer new options for Chinese ADHD kids.
HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001 Biotech Newswire
March 24, 2025
HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001
FDA Approves New Prostate Cancer Imaging Agent Gozellix® PR Newswire
March 21, 2025
Telix Pharmaceuticals Limited announces that the FDA has approved its New Drug Application (NDA) for Gozellix®.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China PharmaSources
March 20, 2025
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer PR Newswire
March 19, 2025
Shanghai Henlius Biotech announced that FDA has granted ODD for HLX22 for the treatment of gastric cancer.
Henlius Receives Orphan Drug Designation for HLX22 in the U.S. for Gastric Cancer PR Newswire
March 19, 2025
Henlius announced that FDA has granted ODD for HLX22, the company's innovative anti-HER2 mAb for the treatment of gastric cancer.